Papers being presented at the American Society of Hematology Conference, December 2007:
- Title: Early Results of Pentostatin, Cytoxan, Rituximab (PCR) Followed by CAMPATH-H (CA) for the Treatment Of Relapse/Refractory Chronic Lymphocytic Leukemia (CLL) in ECOG Protocol E2903
- Title: [1] Identification of RPS14 as the 5q-Syndrome Gene by RNA Interference Screen.
- Title: [1454] Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.
- Title: [1457] A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).
- Title: [1470] Deferasirox (ICL670; Exjade ) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS).
- Title: [159] Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.
- Title: [3553] A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF).
- Title: [821] Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS).
Paper presented in abstract form at the 48th annual meeting of the American Society of
Hematology, Orlando, FL, December 9-12, 2006. Blood First Edition Paper, prepublished online September 24, 2007; DOI 10.1182/blood-2007-01-068833
- Title: Phase II study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Paper published in the New England Journal of Medicine, October 5, 2006
- Title: Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
